News
Read the latest from M8.
Sep 20, 2023
Acino Significantly Expands Presence and Capabilities in Latin America Through Acquisition of M8 Pharmaceuticals

Aug 01, 2023
M8 Pharmaceuticals obtains market authorization for Barlo® (Carragelose®) nasal spray in Mexico

Feb 28, 2023
M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo™ (Enavogliflozin) for Brazil and Mexico

Oct 03, 2022
moksha8 officially rebrands as M8 Pharmaceuticals
May 05, 2022
M8 Pharmaceuticals Announces approval of Mokbio® PS128™ in Mexico

Oct 05, 2021
M8 Pharmaceuticals Announces License of Exclusive Mexican Rights for Arlevert® from HENNIG ARZNEIMITTEL

Sep 14, 2021
M8 Pharmaceuticals Announces License of Exclusive rights for Diacomit® (Stiripentol) from Biocodex SAS

Aug 31, 2021
M8 Pharmaceuticals Announces License of Exclusive rights MED3000 from Futura Medical for Latin America

Partner with Us
From go-to-market strategy and registration to access and long-term market presence, M8 is a purpose-built biopharmaceutical platform that supports the entire development-commercialization continuum.
Work with Us
Our motivated team fosters a supportive and positive culture fueled by the will to bring value to the patients of Latin America.
M8 Pharmaceuticals Announces approval of Mokbio® PS128™ in Mexico
May 05, 2022

M8 Pharmaceuticals announces that its Mexican Affiliate has obtained COFEPRIS approval of MOKBIO® the first psychobiotic L. plantarum PS128™ in Mexico. MOKBIO® capsules is the first M8 original product approved in Mexico, a probiotic strain with support and studies to address the needs of patients with central nervous system disorders. These include MOKBIO® PS128's potential neurological and mental health benefits, such as improving sleep and reducing symptoms like those seen in those patients suffering from anxiety, depression, autism, and Parkinson's disease.
The product has been launched in several European countries and North America. M8 expects to bring the benefits of a new range of psychobiotics to Latin American patients, starting with Mexico. Psychobiotics are probiotics that can yield specific benefits to the nervous system. By modulating the gut-brain axis, MOKBIO® PS128™ has been shown to adjust levels of neurotransmitters, such as dopamine and serotonin. Products that contain these clinically proven strains are formulated to improve mental health and neurological conditions in children and adults.